NCT05825365View on ClinicalTrials.gov

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Neurofibromatosis Type 1Plexiform NeurofibromasPost-operative
Interventions
DRUG

Selumetinib

Selumetinib

DRUG

Placebo

Placebo (Transfer to selumetinib on REiNS-defined PD)

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY